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Abstract Atherothrombosis is a leading cause of cardiovascular mortality and long-term
morbidity. Platelets and coagulation proteases, interacting with circulating cells
and in different vascular beds, modify several complex pathologies including athero-
sclerosis. In the second Maastricht Consensus Conference on Thrombosis, this theme
was addressed by diverse scientists from bench to bedside. All presentations were
discussed with audience members and the results of these discussions were incorpo-
rated in the final document that presents a state-of-the-art reflection of expert
opinions and consensus recommendations regarding the following five topics:
1. Risk factors, biomarkers and plaque instability: In atherothrombosis research, more focus
on the contribution of specific risk factors like ectopic fat needs to be considered;
definitions of atherothrombosis are important distinguishing different phases of disease,
including plaque (in)stability; proteomic and metabolomics data are to be added to
genetic information.
2. Circulating cells including platelets and atherothrombosis: Mechanisms of leukocyte and
macrophage plasticity, migration, and transformation in murine atherosclerosis need to
be considered; diseasemechanism-based biomarkers need to be identified; experimental
systems are needed that incorporatewhole-blood flow to understand how red blood cells
influence thrombus formation and stability; knowledge on platelet heterogeneity and
priming conditions needs to be translated toward the in vivo situation.
3. Coagulation proteases, fibrin(ogen) and thrombus formation: The role of factor (F) XI in
thrombosis including the lower margins of this factor related to safe and effective
antithrombotic therapy needs to be established; FXI is a key regulator in linking platelets,
thrombin generation, and inflammatory mechanisms in a renin–angiotensin dependent
manner; however, the impact on thrombin-dependent PAR signaling needs further study;
the fundamental mechanisms in FXIII biology and biochemistry and its impact on
thrombus biophysical characteristics need to be explored; the interactions of red cells
and fibrin formation and its consequences for thrombus formation and lysis need to be
addressed. Platelet–fibrin interactions are pivotal determinants of clot formation and
stability with potential therapeutic consequences.
4. Preventive and acute treatment of atherothrombosis and arterial embolism; novel ways and
tailoring? The role of protease-activated receptor (PAR)-4 vis à vis PAR-1 as target for
antithrombotic therapy merits study; ongoing trials on platelet function test-based
antiplatelet therapy adjustment support development of practically feasible tests; risk
scores for patients with atrial fibrillation need refinement, taking new biomarkers
including coagulation into account; risk scores that consider organ system differences
in bleeding may have added value; all forms of oral anticoagulant treatment require
better organization, including education and emergency access; laboratory testing still
needs rapidly available sensitive tests with short turnaround time.
5. Pleiotropy of coagulation proteases, thrombus resolution and ischaemia–reperfusion:
Biobanks specifically for thrombus storage and analysis are needed; further studies on
novelmodified activated protein C–based agents are required including its cytoprotective
properties; new avenues for optimizing treatment of patients with ischaemic stroke are
needed, also including novel agents that modify fibrinolytic activity (aimed at plasmino-
gen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor.
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Introduction
During the second Maastricht Consensus Conference on
Thrombosis (MCCT), atherothrombosis and cardiovascular
disease (CVD) were tackled from different angles by basic
and clinical scientists, younger as well as seasoned experts
from an international background. Concise presentations on
subtopics within a larger theme (www.mcct.eu) were held,
followed by discussion sessions (presenters, students, other
attendants) to outline targets for future research. Based on a
plenary synthesis of all sessions, a final consensus document
summarizing all topics and recommendations (►Fig. 1) was
drafted based on the notes from all contributing authors and
condensed into this position paper. This document does not
intend to provide a comprehensive overview of the field;
primarily it reflects the personal interests and opinions of
the experts and input from the audience.
Risk Factors, Biomarkers and Plaque
Instability
Atherothrombosis occurs in the course of atherosclerosis, a
conditiondrivenbychronic inflammation.1,2Currentconcepts
on ‘thomboinflammation’3 also fit in the context of athero-
thrombosisdrivenby the interplaybetween inflammationand
coagulation as a critical mechanism.4,5 Obesity is one of the
main drivers of chronic inflammation in atherogenesis.
Obesity, Ectopic Fat and Thromboinflammation
Obesity is a worldwide health problem with increasing pre-
valence.6 Although obesity is heterogeneous, approximately
30% of obese individuals remain healthy into old age.7 Ectopic
fat accumulation rather than overall obesity is responsible for
increasedcardiometabolic riskand isabetterpredictor forCVD,
including atrialfibrillation (AF) andheart failure.8–10Ectopic fat
refers to fat that accumulates in or around specific organs or
compartments and include abdominal viscera (visceral fat),
liver (intrahepatic fat), heart (pericardial fat), and blood vessels
(perivascular fat). Recent findings support an independent
contribution of ectopic fat deposition to cardiovascular risk.11
Strengthening research on the contribution of ectopic fat
depots to cardiometabolic risk and risk of CVD is necessary.
Adipose tissue is a dynamic endocrine organ consisting of
adipocytes and nonadipocytes including immune cells. Excess
ectopic fatmayexertharmful effects bydirect lipotoxicity, orby
achronicproinflammatoryeffect, at both thelocal andsystemic
level. The impact of ectopic fat on CVDmight occur at different
stages of disease progression. The growth of fat mass leads to
changes in the adipocyte cell size and number as well as in the
pattern of immune cells with an exacerbated presence of
macrophages and lymphocytes, with a proinflammatory phe-
notype. This leads to a deregulated expression of bioactive
molecules including cytokines and adipokines, which contri-
bute to inflammation, endotheliumdysfunction, progressionof
atherogenesis, and a prothrombotic state, all increasing cardi-
ovascular risk.12,13 Further research should unravel differences
between fatdepots incell composition, inflammatory response,
and cell-signaling pathways and ultimately how this translates
into atherosclerosis.
Traditionally, obesity is determined through the body
mass index (BMI), but clearly, the pattern of fat distribution
is more important than the absolute amount of stored fat; it
is conceivable that ectopic fat becomes the diagnostic and
therapeutic target in cardiometabolic disorders shifting the
Fig. 1 Visual representation of the consensus recommendations regarding (1) risk factors, biomarkers and plaque instability; (2) circulating
cells including platelets and atherothrombosis; (3) coagulation proteases, fibrin(ogen) and thrombus formation; and (4) preventive and acute
treatment of atherothrombosis and arterial embolism; novel ways and tailoring?
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focus from quantity (obesity) to quality (dysfunctional fat).14
Current methodologies for tracking ectopic fat distribution
are limited to expensive imaging techniques (e.g. computed
tomography [CT], magnetic resonance imaging [MRI]).15
Genetics and Cardiovascular Disease
For the advancement of prevention in CVD, improving the
accuracy of genetic risk stratification will be of major im-
portance. Single nucleotide polymorphisms increasing the
risk of CVD via interference with inflammation, lipids, blood
pressure, nitric oxide/cyclic guanosine monophosphate sig-
naling, vascular remodelling, and plaque formation have
been detected.16 Several research groups have addressed
the implementation of these genetic variants into genetic
risk models for arterial thrombosis.17,18 Nevertheless, cur-
rent guidelines recommend only standardized assessment of
family history of premature CVD and discourage the general-
ized use of DNA-based test for risk assessment.19 Since
current treatment concepts predominantly focus on the
therapy of disease phenotypes and our understanding of
organ-specific gene translation is still limited, more efforts
are needed to unravel gene–gene and gene–environment
interactions in a systems-medicine–oriented approach.
To improve current knowledge about the translation of
genotype into phenotype, integrative data analysis and deep
clinical phenotyping for subclinical disease will be required.
Therefore, epigenetic, proteomic, andmetabolomic information
shouldbeanalysed inconjunctionwithgenomicdatato improve
the understanding of the pathophysiology of CVD and to
advance the prevention of CVD. Considering the required sam-
ple size and the expertise in ‘omics-technology’ and bioinfor-
matics needed to study the complex interplay of genetic
variation and its functional role, combined efforts (e.g. in
consortia) will be needed. These efforts should be accompanied
byan interdisciplinarydiscussiononethicalaspects, asadvance-
ments in the field of genetics will entail novel ethical demands
for regulatory authorities, health care providers and patients.
Phenotyping the Atherothrombotic Lesion
Tissue composition of plaques rather than the degree of
luminal stenosis determines the vulnerability of an athero-
sclerotic plaque to develop disruption followed by thrombo-
sis.20 A thin fibrous cap, large lipid-rich necrotic core, low
amount of collagen, and high inflammatory activity are major
determinants of plaque vulnerability.2,21 Tissue characteristics
of high-risk plaques can now be visualized with the use of
invasive vascular imaging techniques, which has created con-
siderable progress in defining the composition of plaques in
patients. Intravascular ultrasound with virtual histology ana-
lysis provides a cross-section viewof the entire vessel wall and
allows to detect the thickness of afibrous cap and size of a lipid
core.22 Optical coherence tomography (OCT) provides higher
resolution imaging but limited depth penetrance, with more
detailed information on the near lumen morphology such as
fibrous cap structure, superficial macrophage accumulations,
or plaque rupture.23 However, imaging of the activity and
specific location of inflammatory cells and their secretory
products in plaques is less succesful.24 Some progress has
been made in experimental settings. For example, a critical
step in the destabilization of plaques is the secretion ofmatrix-
degrading metalloproteinases (MMPs) by inflammatory
cells.25 With the use of single-photon emission computed
tomography/micro-CT imagingwith radiolabelledmetallopro-
teinase inhibitors, MMP activity could be detected in animals
(rabbits) in a noninvasive manner.26 And in humans, applica-
tion of near-infrared autofluorescence imaging appeared
successful in detecting fluorescence of naturally occurring
molecules in necrotic cores of high-risk plaques, which pro-
vides some information about the biological activity inside a
lesion.27 Such noninvasive imaging techniques describing pla-
que phenotype over time could elucidate the relation between
inflammation, plaquevulnerability, and clinical events. Still, up
to now it remains a challenge to predict plaque rupture in
individual patients.28 Therefore, there is a call for new defini-
tions and risk assessment strategies regarding atherothrom-
bosis. Besides morphology of plaques, vulnerability of blood
(e.g. hypercoagulability and inflammation) is a contributor to
atherothrombosis.28
There is a knowledge gap with respect to biomarkers of
ongoing plaque destabilization. Pathologic analysis of throm-
bectomyspecimens retrieved fromacutemyocardial infarction
(AMI) patients has revealed huge variations in the propagation
of thrombosis afteronsetofplaque rupture. Stratificationof the
so-called fresh (<1 day) and old (>5 days) thrombi should also
be considered.29 Old thrombus is an independent predictor of
mortality in AMI patients, which probably relates to their
fragile structure and inherent risk of embolization.30 For
example, MMP content of such thrombi is much higher than
in the underlying plaques. Therefore, also thrombus instability
appears a matter of concern and the cellular pathways leading
to thrombus healing (stabilization) or otherwise embolization
or progression to full luminal occlusion need to be further
elucidated. Combiningmorphological characteristics with bio-
markers of vulnerable blood, plaque vulnerability, and throm-
bus instability shouldresult inapan-arterial approach inwhich
atherothrombotic risk establishment becomes more accurate.
Utility of Biomarkers
Meta-analyses of prospective studies have establishedpositive
associations of circulating levels of fibrinogen, vonWillebrand
factor (VWF),fibrinD-dimer, and tissueplasminogenactivator
with risk of coronary heart disease (CHD) and stroke. These
data support the concept of coagulation activity as an impor-
tant contributingmechanism in the processes of atherosclero-
sis as well as thrombosis. The biomarker data are not yet
comprehensive and in particular further studies are required
to establish the associations of other coagulation proteins,
including those from the contact system, with risk of CHD and
CVD.31Given their importance aspotential therapeutic targets
in CVD, additional biomarkers for vWF, factors VIII, IX, XI, and
XII merit further research.32
D-dimer level is associated with risk of stroke in patients
with AF,33 irrespective of anticoagulant drugs.34 Prospective
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studies are required to establish its potential role in risk
stratification, its relationship to other coagulation activation
markers (e.g. prothrombin F1 þ 2), and other biomarkers (e.g.
CRP, troponin and pro-NT-BNP).35 These may inform future
management into two directions. One route concerns the
optimized selection of patients who benefit most from antic-
oagulant treatment (e.g. the discussion in theme4 on theneed
for improved selection of patientswith AF). A seconddirection
would involve, if possible, dose titration in high-risk subjects.
An indication for itspotential comes fromstudies showing that
D-dimer level while on anticoagulation predicts ischaemic
stroke risk in patients with AF.36
Recommendations from Theme 1
• Future research should focus on identifying biomarkers of
ectopic body fat content and distribution and on devel-
oping clinical algorithms including ectopic fat assessment
for cardiovascular risk stratification.
• Genetic risk stratification, including family history, gene–
gene and gene–environment interactions, as well as co-
morbidity needs to be explored; integrative data analysis
and deep phenotyping are crucial. Proteomic and meta-
bolomic data need to be implemented with genomic data
in multicentre trials.
• Develop new definitions and risk assessment strategies
for atherothrombosis, potentially combining morpholo-
gical characteristics with biomarkers of ‘vulnerable blood’
as well as for plaque destabilization to optimize athero-
thrombotic risk stratification.
Circulating Cells Including Platelets and
Atherothrombosis
New insights in the diversity and functionality of monocytes
(macrophages), leukocytes, and platelets were discussed.
The importance of microvesicles (MVs) was recently dis-
cussed in this journal.37
Leukocytes in Atherothrombosis
The importance of leukocytes in the pathophysiology of
atherosclerosis has been well recognized. T lymphocytes
and monocytes/macrophages are abundantly present in
atherosclerotic lesions, and strategies that modulate the
abundance of these cells show strong effects on the extent
of atherosclerosis, at least in mouse models. Also B cells,
divided into twomain families, provide important protective
effects against atherosclerosis (B1), while B2 cells are
thought to be atherogenic.38,39 Mouse models have also
revealed roles of polymorphonuclear cells, most notably
neutrophils and mast cells, in the pathophysiology of ather-
osclerosis.40,41 Lineage tracing and specific labelling of leu-
kocyte subtypes in vivo, along with innovative strategies to
deplete certain leukocyte subsets in mice, have led to the
identification of important contributions of almost any
leukocyte subtype tested.39,42–44 However, there is still no
viable therapeutic or preventive strategy that directly targets
leukocytes.
The puzzle is more complex than initially assumed. First,
the cell content of the plaque is quite dynamic. Although
influx of leukocytes is still believed to be crucial in plaque
development, emigration of immune cells from plaques (e.g.
to nearby lymphoid organs) also plays a role.45 Interestingly,
mouse studies revealed that local proliferation outweighs
infiltration and is the major determinant of macrophage
numbers in the plaque.46 Smooth muscle cells (SMCs) that
are highly abundant in plaquesmigrate from themedia to the
intima, where they proliferate. SMC can also turn into
macrophage-like cells with phagocytic activity and the
excessive ingestion of lipoproteins causes them to degen-
erate into foam cells, much like classicalmacrophages.47,48 In
general, mousemodels of atherosclerosis will remain to have
utility, but their importance in basic pathophysiologic re-
searchmight decline, as the emergence of the ‘omics’ class of
technology (e.g. genome-wide association studies, proteo-
mics and RNA sequencing)will gradually take over their roles
in human cohorts. This might even lead to the identification
of drug principles targeting leukocyte dynamics, once its role
in plaque development is fully understood.
Macrophages and Signaling Effects
Monocytes and neutrophils contribute to venous thrombo-
sis.49 Recent studies show that myeloid cell tissue factor (TF)
activation in thrombosis is linked to complement activation.50
Remarkably, complement factor (C) 3 plays a pivotal role in
platelet activation independent of full complement activation
downstream of C5. C5 nevertheless is crucial for outer mem-
brane phosphatidylserine exposure and activating TF pro-
thrombotic activity, as previously also demonstrated for
complement fixing antibodies causing thrombotic complica-
tions in stem cell therapy.51 Protein disulphide isomerase
pathways are necessary for affinity maturation of TF and
phosphatidylserine exposure but is not sufficient to render
MV-associated TF fully prothrombotic.52 Complement-depen-
dent release of MV from monocytes in LPS-stimulated whole
blood produces TF which due to its high affinity is already in
complex with its ligand FVIIa.
Venous thrombosisandatherothrombosisarelikelydrivenby
distinct but partially overlapping pathophysiological interac-
tionsofbloodandvesselwall cells.53Atherothrombosis is closely
tied to inflammation and interleukin 1β (IL1β) is one of the
inflammatory cytokines implicated as a risk factor for arterial
occlusive events. Indeed, the recently published CANTOS trial
providesproofofconceptevidence in showing clinical efficacyof
the administration of an anti-interleukin-1β antibody in redu-
cing cardiovascular events.54 Macrophages in atherosclerotic
lesions are rich sources of TF, but macrophage-expressed TF is
also largely in a noncoagulant state. Cell injury signals, specifi-
callyATPtriggeringtheprothromboticP2  7receptor,55 induce
a thioredoxin-reductase–dependent inflammasome and cas-
pase-1 activation in primed macrophages. Active caspase-1
simultaneously generates active IL1β and is responsible for the
terminal releasestepofhighlyprothromboticMVcarryingactive
TF.56 These data provide evidence for a direct mechanistic
coupling of thromboinflammatory pathways. It will be of inter-
est to further studywhether this close couplingof inflammation
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and coagulation is common to other activators of the inflamma-
some. Since macrophages in atherosclerotic lesions express the
P2  7 receptor,57 a possible role of this receptor in lesion
thrombogenicity should be investigated.
Coagulation also directly influences atherosclerotic lesion
progression through effects on leukocytes.58 It is notable that
expression of coagulation factors by macrophages is not
restricted to TF. Lung and peritoneal macrophages express
FVII in mouse and man59,60 and tumour macrophages pro-
duce FVII and FX.61 It is an intriguing possibility that macro-
phage phenotypes in atherosclerosis are directly regulated
by signaling through protease-activated receptors (PARs).
PAR2 in particular has been implicated in the regulation of
macrophage activation62 and chronic inflammation in obe-
sity.63 It will be of interest to determinewhether coagulation
factors synthesized by macrophages have effects on lesions
progression, stabilize plaque structure, or contribute to
lesion thrombogenicity. While coagulation inhibitors may
broadly interfere with thrombosis-related pathways, experi-
mental studies can more precisely define the contributions
of intravascular and vessel wall compartments to lesions
progression. Translating experimentalfindings into the clinic
will require the development of new diagnostic, biomarker,
and imaging approaches based on these mechanistic studies
in thromboinflammation.
Red Blood Cells
Inhealthyhumans, redbloodcells (RBCs)occupyapproximately
35 to 45% of the blood volume and elevated haematocrit has
been associated with increased risk of both arterial and venous
thrombosis (reviewed in Byrnes and Wolberg64). RBCs have
biophysical and biochemical properties that contribute to
thrombusformation. Forexample,RBCsaremajordeterminants
of blood viscosity, and increased viscosity has been associated
with risk of cardiovascular events.65 In vitro studies suggest
RBCs promote platelet interactions with the vessel wall,66,67
expose phosphatidylserine, support thrombin generation,68–72
bindfibrinogenandfibrin, anddecrease clot permeability73and
susceptibility to fibrinolysis.74 Studies are needed to determine
whether RBCs are causative in thrombus formation.
Although RBCs are present in both arterial and venous
thrombi, their local function as well as their beneficial or
pathological effects during thrombus evolution remains
unknown. For example, heme deposited by decomposing
or phagocytized RBCs may alter recruitment or function of
other blood cells within the clot. Compaction of RBCs by
platelet-mediated contractile force may stabilize thrombi
and prevent embolization, but may prolong thrombus reso-
lution. Experimental systems that incorporate blood flow,
RBCs, platelet-mediated contraction, thrombin generation,
and fibrinolysis are needed to understand how RBCs influ-
ence thrombus formation and stability.
Platelet Pleiotropy: Different Platelets, Different
Functions
The concept of interplatelet heterogeneity75 is receiving in-
creased interest. Platelets from an individual donor can differ
in glycoprotein receptors expression levels and activation.
Circulating platelets differ in mRNA content and capacity to
translation, depending on their life time.76 Furthermore, pla-
telets undergoing secretion can differ in the process of secre-
tory granule fusion and exocytosis.77 On the other hand,
platelets assembling in a growing thrombus diverge into (1)
aggregated and contracted platelets of the thrombus core; (2)
transiently adhered platelets of the outer thrombus shell; and
(3) highly activated, procoagulant platelets in thrombus
patches.75 This raises the intriguing question if the known
pleiotropy in platelet functions implies that different popula-
tions of platelets are ‘specialized’ in carrying out different
functions. Several key elements in the life of platelets that are
worth further investigation can be identified:
1. Difference between individual megakaryocytes and plate-
lets. Despite visualization of (pro)platelet production in
the bone marrow,78 it is unknown how megakaryocytes
regulate the numbers of receptors per formed platelet. A
current assumption is that a certain megakaryocyte pro-
duces similar (pro)platelets, but cultured megakaryo-
cytes, even when produced from a single-cell clone of
hematopoietic precursors, show a remarkably large inter-
cellular variability in surface receptor expression.79 This
raises the possibility that different megakaryocytes in the
bone marrow can form different ‘types’ of platelets.
2. Priming of platelets (macroenvironment). Due to the pre-
sence of circulating hormones or other biomolecules, plate-
lets can be primed to become more or less responsive to
agonists.80 Priming can occur rapidly, and be followed by a
prolonged period of sensitization or desensitization.81 Gi-
ven the differences inmakeup of individual platelets, some
platelets may be more prone to priming than others. Both
acute and chronic disease conditions may act as primers,
either through exposure to tissue damage or through
inflammatory mediators or pathogens.
3. Platelet populations in a thrombus (microenvironment).
Densely aggregated and contracted platelets have been
observed in the thrombus core, surrounded by an outer
shell ofmore loosely attached platelets.82 Surrounding the
aggregated platelets, patches of highly activated platelets
are seen with a specialized function in coagulation.75
Likely, the microenvironment (e.g. the direct exposure
of platelets to collagen and thrombin) plays a role in this
platelet heterogeneity.
4. Platelet age and size. Platelets circulate in the blood stream
for 7 to 11 days. There is debate whether newly formed
platelets are larger in size and more active than aged
platelets. Such associations have been measured, but
these are weak. Increased mRNA content of the younger
platelets may direct platelet function and fate and even
the vesiculation of platelets.
5. Platelet heterogeneity in vivo versus in vitro. The properties
and even the populations of isolated platelets can differ
(e.g. with respect to priming) from the properties of
platelets circulating in the blood. Moreover, in vivo pre-
activated platelets will be more prone to being cleared
than inhibited platelets, whereas both can stay in suspen-
sion after isolation.81 This brings about a need for new
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technologies to study single-cell activation properties of
platelets in vivo and in vitro, and a requirement for
standardized isolation of platelets without affecting their
priming state.
Recommendations from Theme 2
• Address mechanisms of leukocyte plasticity, migration,
and transformation in murine atherosclerosis; various
‘omics’ technologies have the potential to take over the
role of mouse models in human cohorts.
• Characterize the role of haemostatic factors in macro-
phages related to inflammation and atherothrombosis;
develop mechanism-based biomarkers.
• Investigate the causal contribution of RBCs in thrombus
formation.
• Incorporate whole blood flow in experimental systems to
assess how RBCs influence thrombus formation and
stability.
• Improve knowledge on platelet heterogeneity, how this
translates into the formation of platelet populations by
megakaryocytes, how to translate from single-cell (plate-
let, megakaryocyte) assays to the in vivo situation? In-
vestigate how platelet priming fits into the pathogenesis
of thrombotic disease (cause or consequence?).
Coagulation Proteases, Fibrin(Ogen) and
Thrombus Formation
Factor XI
Factor XI (FXI) is a pivotal protein in the coagulation cascade,
as it links the contact system with thrombin and fibrin
formation, and it also determines the flux through the
coagulation cascade after TF exposure via thrombin-
mediated FXI activation.83 Drugs targeting FXI can be effec-
tive for thrombosis prevention, but there are no data show-
ing that FXI targeting is useful in the treatment of
thrombosis. An intervention study in humans who under-
went total knee replacement demonstrated that reducing
FXI levels by antisense oligonucleotides (ASO) was effective
and safe.84 This study was carefully chosen, since knee
replacement introduces a medical device, which likely acti-
vates the contact system. Furthermore, the TF concentration
in knees is very low, meaning that the amplification of
thrombin formation via FXI becomes relatively important.85
The bleeding tendency in FXI deficiency is most often
trauma related especially in tissues with high local fibrino-
lytic activity, while spontaneous bleeding is rare, and there-
fore low levels of FXI appear to be safe. Preclinical and clinical
studies suggest that complete deficiency is not necessary to
effectively prevent thrombosis; a level of 20 to 30% FXI is
effective and expected to result in less bleeding compared
with complete inhibition.
The optimal approach to target FXI is still debated.86
Vaccination (probably not reversible) and ASO have the
disadvantage of a slow onset of action. The use of small
molecules and (monoclonal) antibodies requires additional
studies, also considering potential off-target effects of these
approaches.
Coagulation (Factor XI) and Its Link with Platelets and
Hypertension: A Novel Risk Mechanism
Recent experimental and early clinical data suggest that target-
ing FXI could be effective in treating vascular inflammatory
conditions that go beyond treating clotting disorders. FXI defi-
ciency improved survival in polymicrobial sepsis87 and pro-
tected from disease progression in atherosclerotic mice.88
Individuals with congenital FXI deficiency are partially pro-
tected from myocardial infarction and stroke, both sequels of
chronically increased blood pressure.89 FXI ASO application
prevented arterial hypertension and reduced established
hypertension in animal models. This effect was connected to
interruption of the thrombin-FXI amplification loop involving
glycoprotein (GP)Ibα on platelets, attenuating the proinflam-
matory state of platelets and reducing vascular accumulation of
inflammatory leukocytes, endothelial dysfunction, and tissue
remodelling in response to high blood pressure. The FXI-de-
pendent platelet-localized amplification of FII was validated in
humans with uncontrolled hypertension.90
Since thrombin propagation is essential in the observed
non–clotting-related effects, thrombin signaling, which is
likely mediated through PARs, must be further explored.
Since PAR-1 is expressed on monocytes, endothelial cells
and SMCs alike, the thrombin-signaling through PAR-1 needs
to be investigated in greater detail to understand possible
beneficial off-target and/or disease modifying effects of
direct thrombin inhibitors like dabigatran. However, RELY
investigators91 so far have not reported on alterations in
blood pressure in patients on dabigatran treatment.
If the FXI-mediated effects were all related to propagation
of thrombin formation, patients with haemophilia A or B
should also have lower blood pressure. However, the con-
trary is the case; this may be due to inflammatory responses
associated with repeated episodes of severe bleeding that
might potentially override a putative ‘antihypertensive’
effect of FIX or FVIII deficiency. An additional potential target
is the GPIbα, the receptor on platelets to which thrombin as
well as FXI but also the MAC-1 integrin on leukocytes and
VWF can bind.
FXI has a striking homology to pre-kallikrein (PK). Deple-
tion of FXI (e.g. by an ASO approach) might cause counter-
regulatory upregulation of PK with ensuing activation of
bradykinin, which might directly cause vasodilation and
blood pressure lowering in a nitric oxide–dependent man-
ner. It should be evaluated whether targeting of C1-esterase
inhibitor, a natural FXIa inhibitor, would affect blood pres-
sure. Furthermore, using small molecules targeting FXIa92
should be considered to evaluatewhether inactivation of the
active protease is equally effective in influencing blood
pressure as the ASO approach. This is of interest, as non-
specific effects of ASOs on platelet count and function93
could impact on vascular function independently of the
protease activity of FXI. Datasets of the aforementioned
FXI ASO clinical trial and population-based cohorts (e.g.
Clalit Health Service database,89 Gutenberg Health Study94)
should be explored for associations of FXI activity or single
nucleotide polymorphisms in the FXI gene with vascular
function, hypertension, or incident CVD.
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Factor XII, Polyphosphates, Prekallikrein and High-
Molecular-Weight Kininogen
The FXII-driven contact system and its endogenous activator
polyphosphate (polyP) play important roles in thrombosis.95
In contrast to FXI deficiency, FXII-deficient humans do not
suffer from any abnormal bleeding. Targeting the contact
system or polyP represents promising therapeutic targets for
prevention of or interferencewith thrombotic disorders.96,97
In addition, activated FXII induces potent inflammatory
responses via activation of the kallikrein-kinin system re-
sulting in the formation of the inflammatory mediator
bradykinin.98 The dual role of FXII in thrombosis and in-
flammationmakes it an attractive therapeutic drug target for
anticoagulation without any bleeding risks and additional
anti-inflammatory activities.99,100
Prekallikrein circulates inplasmabound tohigh-molecular-
weight kininogen (HK), thebradykininprecursor. Uponactiva-
tion by FXIIa, prekallikrein is converted to plasma kallikrein
and then reciprocally amplifies further FXII cleavage that in
turn produces additional plasma kallikrein.101,102 Similar to
FXII, plasma kallikrein-deficient mice have an antithrombotic
phenotype and do not bleed excessively.103 As plasma kallik-
rein functions mostly as an amplifier of the coagulation
cascade, its deficiency can be overcome by strong contact
activators which limits its potential use as target for antic-
oagulation.98However, targeting plasma kallikrein has proven
beneficial effects for interference with bradykinin-driven in-
flammation such as hereditary angioedema.104,105
Inhibition of HK seems to be another promising strategy for
safe thromboprotection as suggested from mouse models. In
contrast tohumans,micehavetwokininogengenesandablation
of kininogen 1 (mkng1/ mice) protects from experimental
arterial thrombosis without causing bleeding.106 Consistently, a
patient with plasma kininogen activity of less than 1% did not
bleed.106 While serine proteases are targetable by small mole-
cule inhibitors thatbind into theenzymaticpocket, strategies for
interference with HK or HK expression should be further
investigated.
PolyP, a linear polymer consisting of a few to several
hundred residues of orthophosphate linked by phosphoan-
hydride bonds, initiates coagulation in a FXII-dependent
manner.107 Platelets contain two pools of polyphosphate.
Short-chain soluble polyP with low FXII activating capacity
are released from platelet dense granules. The majority of
platelet polyP, however, forms nanoparticles (similar to
other FXII activators such as kaolin or ellagic acid) with
divalent metal ions (mostly as Ca2þ) that are retained on
the surface of platelets and potently activate FXII.107 The role,
structure, and composition of these nanoparticles in throm-
botic conditions warrant further investigation.
Factor XIII
Factor XIII is unlike other coagulation enzymes in its ability
to crosslink, rather than cleave, proteins within the clot. FXIII
(FXIIIa) activity is essential for clot biochemical andmechan-
ical stability.108 Several FXIII polymorphisms appear to
modify thrombosis risk;109,110 these function, in part,
through complex interactions that mediate the kinetics of
FXIII activation and fibrin crosslinking.111,112 FXIII activity
also promotes retention of RBCs within clots during platelet-
mediated clot contraction.113 However, fundamental me-
chanisms in FXIII biology and biochemistry and its impact
on thrombus biophysical characteristics remain unclear.
Although studies suggest FXIIIa can be proteolytically
inactivated,114 endogenous inhibitors of FXIIIa have not
been identified. Importantly, currently available FXIIIa in-
hibitors lack the pharmacological properties necessary for in
vivo investigations.
FXIII is found in both plasma and cellular compartments,
but the relative roles of plasma and platelet FXIII in platelet
function, fibrin crosslinking, and thrombus composition and
stability are poorly understood.
Differences in FXIII expression between humans andmice
should be considered when using animal models.
Fibrin Network Structure
Fibrinogen conversion to fibrin is essential for haemostasis.
Formation of clots with abnormal structure and stability is
associated with haemostatic and thrombotic disorders,
including both arterial and venous thrombosis/thromboem-
bolism.31 Clots with overly dense fibrin network structure
have been associated with enhanced mechanical and bio-
chemical stability and increased risk of thrombosis.65–68
These observations indicate that the clot structure may
be a biomarker of haemostatic and thrombotic potential.
Most studies use in vitro methods to assess plasma clot
structure in the absence of cells, but this approach fails to
reveal contributions of vascular and blood cells to clot
formation and function; these include both procoagulant
and fibrinolytic activities produced by local blood and vas-
cular cells, and mechanical forces imparted by platelets
during clot contraction.
Platelet–Fibrin Interactions and Clot Architecture
Knowledge of fibrin interactions with platelets and their
respective interactions with other blood cells is incomplete.
Platelets bind fibrin through activated αIIbβ3, which also
binds fibrinogen. However, recent studies show that fibrin,
but not fibrinogen, binds GPVI and activates plate-
lets.115,116 The thrombus is not homogeneous, but com-
posed of a core of strongly activated platelets and a
periphery of more loosely activated platelets.117 It is pos-
sible that combined collagen and fibrin interactions with
platelets drive thrombus core formation, while the inter-
action of fibrin with platelets plays a role in determining
the thrombus periphery.
1. Filling the void: there is a need for novel in vitro and in vivo
models to probe interactions between platelets and coa-
gulation. However, studying platelet–fibrin interactions is
practically challenging, as the fibrin mesh that is formed
eliminates several techniques. Vice versa, platelet aggre-
gates interfere with clotting assays. An intermediate stage
of fibrin protofibrils and oligomers precede the gelation
point.118 Further studies are required to determine plate-
let interactions with these fibrin species.
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2. Novel GPVI–fibrin interactions shed new light and should
be investigated in diseases of thrombosis and haemosta-
sis. Recent data indicate that collagen and fibrin bind
distinct GPVI epitopes (Onselaer MB et al, PhD, unpub-
lished data), suggesting that it is possible to specifically
target each ligand interaction. GPVI polymorphisms have
also been associated with venous thromboembolism in
genome-wide association studies.119 It would be inter-
esting to investigate whether GPVI polymorphisms that
result in less active GPVI signaling are also associatedwith
decreased fibrin–GPVI interactions.
3. There couldbeothercoagulationandplatelet interactions that
are currently unknown. Proteins such as vWF,120 fibronec-
tin,121 FXIII,122,123 and α2-antiplasmin124 are incorporated
into thefibrin clot and their role inplatelet interactionswith
the clot in the context of the clot network are incompletely
understood. Furthermore, platelets express several fibrino-
lytic proteins and FXIII on their surface,125,126 which may
interact with the surrounding fibrin network.
4. Interactions with red and white cells. There is evidence for
the binding of red cells to fibrinogen127,128 and plate-
lets.129,130 The implications of these interactions deserve
further study. Neutrophils contribute to thrombosis
through the production of NETs.131 DNA and histones
have been shown to impart resistance to fibrinolysis.132
How DNA and histones interact with fibrin at the fibre
level is poorly understood. White cell incorporation or
invasion into thrombi may also contribute to thrombus
resolution through the production of elastase, which has
been shown to degrade fibrin and FXIII.133,134
Recommendations from Theme 3
• Address the relevance of FXI for treatment of thrombosis
and thromboinflammatory disorders; a ‘safe’ lower level
of FXI targeting thrombotic complications remains to be
determined. Off-target effects of inhibiting FXI need to be
considered.
• Undertake further studies on FXI induced increased
thrombin production and PAR-mediated cell signaling;
these should consider upregulation of PK-mediated acti-
vation of the bradykinin pathways; population-based
cohorts or large trials with anticoagulants should be
explored for signals of blood pressure lowering effects
or changes in incident CVD linked to FXI or other clotting
protease activity.
• Address the dual role of FXII in thrombosis and inflam-
mation in different disorders; investigate strategies for
interference with HK or HK expression; investigate the
role of PolyP nanoparticles on platelets.
• Explore the fundamentalmechanisms in FXIII biology and
biochemistry and its impact on thrombus biophysical
characteristics; development of FXIII(a) inhibitors would
facilitate studies to investigate FXIII(a) function in hae-
mostasis and thrombosis.
• Development of technologies to image fibrin structure and
biophysical characteristics in the presence of blood cells and
in thrombi formed in vivo would yield important insights;
differences infibrinnetwork structurebetween species (e.g.
humans versus mice) should be considered in studies of
fibrin structure and function in health and disease.
• Study the relationships between abnormal fibrin struc-
ture and functional consequences, including susceptibil-
ity to fibrinolysis and mechanical deformability, which
should involve new technologies to imagefibrin structure
and biophysical characteristics in the presence of blood
cells and in thrombi formed in vivo.
• Investigate whether there are additional aspects of the
interaction between platelets, fibrin (e.g. fibrin–GPVI
interactions), and red and white blood cells that play
key roles in thrombosis and haemostasis.
Preventive and Acute Treatment of
Atherothrombosis and Arterial Embolism:
Novel Ways and Tailoring
Inhibition of Protease-Activated Receptor-Mediated
Cell Signalling as Antithrombotic Strategy
Despite the prematurely halted TRACER study due to in-
creases in the risk of moderate and severe bleeding events in
stroke patients, pharmacologic blockade of PAR1 is still
potentially an attractive target for the prevention of several
cardiovascular pathologies, including acute coronary syn-
drome, chronic secondary prevention of ischaemic events,
and peripheral artery disease (PAD).135,136 In the TRA2
P-TIMI 50 study, the PAR1 antagonist, vorapaxar, did meet
primary endpoints with significant reductions in major
adverse coronary events (MACEs) in secondary prevention
in nonstroke patients with prior myocardial infarction and
PAD. In particular, the subgroup of patientswith priorMI also
demonstrated a significant reduction in cardiovascular death
and ischaemic events.137 Despite documented improve-
ments in MACE reduction and approval by Food and Drug
Administration, vorapaxar has not seen widespread use,
especially in the subjects with prior MI, due to the perceived
elevated bleeding risk (especially intracerebral haemor-
rhage). The use of vorapaxar on top of dual antiplatelet
therapy (e.g. triple antiplatelet therapy) may likely have
contributed to the increase in incidence of bleeding events.
Studying the effects of vorapaxar as monotherapy or dual
therapy might reveal reduced bleeding risk and would be
worth testing especially in subjects with prior MI.
One potential explanation of these increased intracranial
bleeds on triple therapy might be that akin to TF and
thrombomodulin, PAR1 is differentially expressed in
endothelial cells of the brain,138 thereby giving rise to
different integrin/leukocyte adhesion, regulation, and hae-
mostatic functions. Another issue with vorapaxar is that it
displays functionally irreversible binding to PAR1 with phar-
macodynamic antiplatelet effects of 4 to 8 weeks.139 As
reversibility is important tomitigate bleeding risk, vorapaxar
may not be practical to use in patients with heightened risk
of bleeding (e.g. older patients, those with low body weight,
or uncontrolled hypertension). Another interesting pharma-
cologic effect to be addressed is why a single dose of
vorapaxar exhibits such a long lasting anti-PAR1 platelet
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effect well after replenishment with fresh platelets 8 to
10 days after drug administration. Does this imply that
vorapaxar binds to megakaryocyte PAR1 and somehow
changes themegakaryocyte behaviour leading to a ‘memory’
effect in the megakaryocyte due to phenotypic switching
or imprinting? Does vorapaxar alter PAR1 expression or
are other critical platelet signaling components downregu-
lated or altered to suppress long-term PAR1 function in the
nascent platelets? The new PAR1 pepducin inhibitor, PZ-128,
which has a fast on-rate and improved reversibility of
recovery of PAR1 platelet function,140 and may provide a
more favorable balance of efficacy and safety, is currently
being evaluated in the phase 2 TRIP-PCI clinical trial in the
United States.
Aside from PAR1, is the lower affinity PAR4 thrombin
receptor inherently a better target than PAR1 because PAR4
blockade causes less bleeding, or is PAR4 a poor target
because PAR1 is the high-affinity thrombin receptor141?
Success in targeting PAR4 or the PAR1–PAR4 heterodimer142
will require achieving efficacy even if safety concerns are not
an issue. Recent identification of a superactive PAR4 poly-
morphism in transmembrane domain-2 (TM2) in blacks
would suggest enriching clinical trials with appropriate
populations to fully understand the pharmacogenomics of
PAR4 inhibitors.143
Optimizing Antiplatelet Therapy by Platelet Function
Monitoring
Dual-antiplatelet therapy, consisting of aspirin and a P2Y12
inhibitor, is the mainstay of treatment for patients with
coronary artery disease undergoing percutaneous interven-
tion, to prevent stent thrombosis.144,145 However, some pa-
tients continuetohave thromboticeventswhile onantiplatelet
therapy, while others suffer from bleeding.146 The degree of
P2Y12 inhibition as measured by platelet function tests (PFTs)
has been related to the risk of both thrombotic and bleeding
events and has led to the concept of a therapeutic window for
optimizing antiplatelet therapy.146–148 Several large clinical
trials have investigated the value of PFT-based tailoring of
antiplatelet therapy. These trials, such as GRAVITAS, TRIGGER-
PCI, and ARCTIC, all failed to prove that intensifying P2Y12
inhibitor therapyprevents thromboticevents inpatientswitha
low response to P2Y12 inhibitors (high on-treatment platelet
reactivity [HTPR]).149–151 The ANTARCTIC trial was the first to
also includeade-escalationarmofantiplatelet therapy incases
of low on-treatment platelet reactivity (LTPR) to prevent
bleeding in the elderly, but this also appeared ineffective.152
Results of the second de-escalating trial, TROPICAL-ACS, are
expected in the third quarter of 2017.153
So, have any of these studies actually proven that the
concept of individualizing antiplatelet therapy based on PFTs
does not improve clinical outcome? Members of the work-
shop felt that this cannot be concluded, due to limitations of
both the trial designs and PFTs. Recognized drawbacks of the
trial designs include (1) the study protocols regarding in-
tensification of P2Y12 inhibition mainly allowed a singular
switch to another drug or dose, (2) the studies had low
statistical power because of a low incidence of primary
endpoints, and (3) patients with a higher risk of recurrent
eventsweremostly excluded (e.g. STEMI).147 The importance
of this last limitation is underpinned by two recent meta-
analyses indicating that both the predictive value of platelet
reactivity for thrombotic events, and the benefit of PFT-
based tailoring of therapy, is dependent on the patient’s
cardiovascular risk profile.154,155
Limitations of PFTs also significantly hinder the measure-
ment of platelet reactivity and optimization of treatment.
Widely used PFTs include light transmission aggregometry
(LTA), PFA-200, multiplate, and the only true point-of-care
test in use, the VerifyNow. Most importantly, these assays do
not reflect normal physiological platelet function. Platelets
tend to be activated with single agonists while in vivo
multiple stimulation occurs, the influence of coagulation
or fibrinolysis is not usually assessed, pleiotropic effects of
the P2Y12-inhibitors cannot be measured, and with the
exception of PFA-200 platelet aggregation ismeasured under
low shear conditions.156 Another limitation of the widely
used PFTs concerns the large influence of preanalytical
variables on the test results, including the type of antic-
oagulant used, delay time from blood withdrawal to mea-
surement, and concentrations of agonists used.156 Finally,
current PFTs lack assay standardization and consensus
regarding optimal cut-offs for HTPR and LTPR.147 One of
the ongoing activities of the ISTH Platelet Physiology SSC is
to publish new guidelines for monitoring of P2Y12-inhibition
(http://www.isth.org/members/group.aspx?id=100371).
Anticoagulation in Atrial Fibrillation: To Treat or Not
to Treat, That Remains the Question!
Patients with AF should ideally be treated by a team of
cardiologists and specialized nurses157—which treats comor-
bidities and decides on anticoagulation therapy. Current ESC
guidelines recommend using the CHA2DS2-VASc score to
guide initiation of anticoagulation therapy in patients with
AF.158 However, there is room for improvement in the
identification of patients who need and tolerate anticoagu-
lation, to prevent overtreatment and reduce bleeding events,
respectively.
The risk factors that are part of the CHA2DS2-VASc score
should be further specified: for example, currently it is not
defined whether left ventricular hypertrophy on echocardio-
graphy should be counted as ‘hypertension’ and whether
coronary artery disease on CT angiography should be counted
as ‘vascular disease’.
There is no consensus on the use of anticoagulation in
patients with one risk factor (CHA2DS2-VASc score of 1 in
men, 2 in women). The ESC guidelines suggest considering
starting anticoagulation,158 while the AHA/ACC suggests con-
sidering not to start anticoagulation.159 Recent large-scale
reports show differing results: there are high stroke rates in
patients with one risk factor not on anticoagulation,160 while
thebleeding riskonwarfarin isexceptionallyhighandprobably
higher than the stroke risk.161 Additionally, AF pattern (i.e.
paroxysmal orpersistent)maybeconsidered in thedecision, as
it may reflect underlying pathology and hence associate with
stroke and bleeding risk.162
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Biomarkers may be used to improve risk stratification (e.g.
the Age Biomarkers Clinical History [ABC] score),163 in which
NT-proBNP and troponin are incorporated. However, it is
currently unknown how this score should be implemented
in daily practice.
Both the CHA2DS2-VASc score and the ABC score identify
those patients who are susceptible to vascular disease, such
as stroke, rather than the patient’s clotting tendency. How-
ever, it has been shown that hypercoagulability may be the
underlying process leading to AF,164 even in vascularly
healthy patients.165 Future risk stratifying strategies may
need to include measurements of hypercoagulability.
There are several imaging strategies that may enhance
identification of patients with a high stroke risk. With
transoesophageal echocardiography, the presence of high-
risk echocardiographic features can be assessed,166 while
echocardiography, cardiac CT, or MRI can be used to assess
left atrial appendage morphology,167 all of which may en-
hance the identification of those patients with a phenotype
prone to stroke.
Current risk scores are validated only for patients with AF
which is recorded on ECG or Holter. Cardiac implantable
electronic devices (CIEDs) continuously monitor the (atrial)
heart rhythm. In case a CIED registers an atrial high rate
event, it is currently unknown whether anticoagulation
should be started. The ongoing randomized NOAH
(NCT02618577) and ARTESiA (NCT01938248) trials will
provide valuable answers for this category.
How to Handle the Risk of Anticoagulant Therapy?
For many years anticoagulation was based on vitamin K
antagonists (VKA). Monitoring of anticoagulant treatment
is done via regular measurements of the international nor-
malized ratio (INR) in a secondary care setting, at least in
several countries. These specialized anticoagulation centres
in which knowledge and experience with VKA treatment is
present play a key role as coordinator of anticoagulation
therapy.
The field of anticoagulation therapy is evolving. Non-VKA
oral anticoagulants (NOAC) have shown to be at least as
effective and safer as VKA in large trials,91,168–170 and are
now changing clinical practice. Dabigatran, rivaroxaban, apix-
aban,andedoxabanare replacingVKAasfirst choice treatment
for several indications. The possibility to prescribe different
types of oral anticoagulants for similar indications is making
anticoagulant treatment more complex.
The balance between the risk of thrombosis and the riskof
bleeding remains an important concern in patients receiving
anticoagulant therapy. Due to a more predictable pharma-
cological profile, routine monitoring is not required for
NOACs. However, this should not preclude regular follow-
up to oversee safety and efficacy of treatment.171 Currently,
there is no standardized follow-up available for patients on
NOAC therapy. The question rises how this follow-up should
be implemented in existing health care systems that are
currently based on VKA management.171,172 We propose a
solution for NOAC follow-up, designed to increase treatment
efficacy and safety, based on expanding the capacity and
capability of current anticoagulation centres, without a big
increase in costs.
The current anticoagulation centres are well trained and
equipped to adequately monitor and guide patients on
VKA, reaching high time in therapeutic range.173 These
centres are local and give centralized coagulation care to a
small population. By educating specialist coagulation
nurses and physicians, their knowledge on NOACs can be
increased. Specific software tools and checklists can help
nurses with systematic assessment of patients on NOACs.
A physician should be available for consultation, but over-
all the anticoagulant care should, ideally, remain nurse
based. Nurses should monitor several aspects, such as the
following:
• Kidney and hepatic function.
• Compliance to drugs, which can also be checked via
information from the pharmacy.
• Weight.
• Blood pressure.
• Adverse events during treatment, i.e. bleeding events.
• Haemoglobin and platelet counts.
• Reassessing the indication for anticoagulation.
Furthermore, haemostasis centres are needed, which
should be regional and should be located in a medical
centre with a multidisciplinary team, for example consist-
ing of a haematologist, cardiologist, neurologist, and a
gastroenterologist.
Organ Specificity of Anticoagulant Effects
The pattern of bleeding with oral anticoagulants differs by
agent.174 Compared with warfarin, all of the NOACs reduce
intracranial bleeding, some NOACs are associated with in-
creasedgastrointestinal (GI) bleeding, and someare associated
with abnormal uterine bleeding.175 Several mechanisms have
beenproposed to explain the organ-specific effects ofdifferent
oral anticoagulants.
First, the mechanisms of action of VKA compared with
NOACs: VKA inhibit the production of vitamin K–dependent
coagulation proteins, whereas NOACs selectively target coa-
gulation factors Xa or IIa.176,177 By targeting multiple coa-
gulation factors, VKAs appear to produce greater inhibition
of thrombin generation than the NOACs,178 which may in
part explain why they are associated with a higher risk of
bleeding. However, this does not explain organ-specific
differences in bleeding.
The second mechanism is related to physiologic differ-
ences between vascular beds of the brain, gastrointestinal
tract, and uterus. The brain is rich in TF and haemostasis is
dependent both on expression of TF on subendothelial
membranes and on low levels of tissue factor pathway
inhibitor (TFPI),179 an inhibitor of the TF/VIIa complex.
By inhibiting factor VII, VKAs prevent the formation of
the TF/VII complex and thereby suppress haemostatic
mechanisms in the brain, whereas this mechanism is
unaffected by the NOACs. This may explain the reduction
in intracranial haemorrhage with NOACs compared with
warfarin. In the uterus, animal studies suggest that factor
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Xa is important in the regulation of haemostasis. This may
explain why factor Xa inhibition by rivaroxaban is asso-
ciated with an increase in abnormal uterine bleeding
compared with warfarin.180
The third mechanism is relevant to excess GI bleeding seen
with several NOACs. The integrity of the GI mucosa can be
disrupted by intraluminal factors,181 and this allows uptake of
drugs from the lumen. VKAs exert their anticoagulant effect by
inhibiting vitamin K epoxide reductase, which requires ab-
sorption from the gut into the systemic circulation, whereas
NOACs are only partially absorbed from the gut and residual
drug can exert effects locally on the GI mucosa leading to
bleeding.174,179,182
The ESC guidelines158 for stroke prevention in AF recom-
mend use of the HAS-BLED score to predict bleeding, but this
score is only weakly predictive. One possible contributor to
its poor predictive value is that it fails to take into account
organ-specific differences in bleeding risk. The future devel-
opment of separate risk scores for intracranial, GI, and
uterine bleeding may improve risk prediction but might
also increase complexity because of difficulties in integrating
the information for individual patients.
Toward Individualized Optimized NOAC Therapy
Although routine coagulation monitoring is not required in
patients taking NOAC, certain clinical situations require
guidance on the intensity of anticoagulation. Currently, there
is no consensus on which clinical situations would benefit
from such occasional monitoring. Some experts propose
specific cut-offs in plasma concentration equivalent to re-
duce the risk of haemorrhagic complications in the perio-
perative setting or to guide the administration of reversal
agents.183–185
Importantly, these different clinical situations require
different test characteristics. For emergency situations, the
question is whether any remaining anticoagulant effect is
still present and a sensitive test with short turnaround time
and a 24-hour availability is essential. Classical coagulation
tests, such as PT, aPTT, and thrombin time, have important
limitations.186–188 For more robust and quantitative pur-
poses, specific assays are available, including diluted throm-
bin time (dTT) or Ecarin chromogenic assay (ECA) for
dabigatran, and NOAC calibrated chromogenic anti-Xa assays
for FXa inhibitors.172,175 The turnaround time of these
specialized assays is similar to the one of routine tests
making them preferable.189 However, rapid, point-of-care,
whole blood tests for use in emergency situations would be
desirable, while other specialized assays such the thrombin
generation test, the thromboelastography or ROTEM, and
other microfluidic assays might offer potential in the near
future.190
Laboratory measurement is useful not only in emergency
situations but also for eventual dose adjustment purposes.
Although the clinical trials with NOACs proved the safety of
the fixed dose policy,91,168–170,191–195 the observed consid-
erable interindividual variation in drug levels in pharmaco-
kinetic studies and clinical trials suggests that dose
adjustment guided by laboratory assays may be appropriate
in some circumstances (provided that registered doses are
used).196–205, a
At present, however, there are neither established ther-
apeutic ranges nor is there evidence-based data supporting
the laboratory approach. At the same time, on-therapy
ranges are available from the large phase 2/3 stu-
dies,201,206–208, b which can be considered in daily practice.
Although this proposal did not reach consensus, we
propose that future studies should focus on the definition
of a ‘therapeutic window’, and explore the possibilities of
tailoring the dose based on these safety margins. This
approach may improve the benefit–risk ratio in elderly/frail
patients.
Other New Anticoagulants
The ideal anticoagulant should prevent thrombosis without
increasing bleeding risk. Additional features could include
low renal clearance, minimal drug–drug/drug–food interac-
tions, good oral bioavailability, and an effective reversal
agent, if required. Importantly, the residual major bleeding
riskwith current anticoagulant drugs is of the order of 2 to 3%
per year in patients with AF209–211 and 1% in patients with
VTE.212 Moreover, the number needed to treat with a NOAC
for preventing one major bleeding event, compared with
VKA, remains high (>100).211,212 Until recently, clinical
anticoagulation has been oversimplified, without addressing
organ-specific processes of bleeding and thrombosis and the
differences in pathogenesis across various clinical scenarios,
as exemplified by bleeding patternswith NOACs.211,212 Thus,
during drug development, indication-specific targeting
should be considered. This includes, for example, researching
contact pathway inhibition for indwelling artificial surfaces
such as catheters or mechanical heart valves, and taking into
account oscillation of drug levels and lack of protective
mechanisms present in normal vessels walls.
NOACs have yet to challenge VKA treatment in rarer sites
of thrombosis, such as cerebral venous sinus thrombosis and
chronic portal vein thrombosis. Patients with mechanical
heart valves are a group in need of new anticoagulants. The
a Food and Drug Administration. Eliquis—Clinical Pharmacology
and Biopharmaceutics Review(s) 2012 [updated October 25,
2016]. Available from: http://www.accessdata.fda.gov/drugsatf-
da_docs/nda/2012/202155Orig1s000ClinPharmR.pdf. European
Medicines Agency. Eliquis—EMEA/H/C/002148/X/04/G 2012
[Available from: http://www.ema.europa.eu/docs/en_GB/docu-
ment_library/EPAR_-_Assessment_Report_-_Variation/human/
002148/WC500136575.pdf].
b European Medicines Agency. Xarelto—Summary of Product
Characteristics 2016 [updated October 14, 2016]. Available from:
http://www.ema.europa.eu/docs/en_GB/document_library/
EPAR_-_Product_Information/human/000944/WC500057108.
pdf; European Medicines Agency. Eliquis—Summary of Product
Characteristics 2017 [updated February 22, 2017]. Available
from: http://www.ema.europa.eu/docs/en_GB/document_li-
b ra r y /EPAR_-_Produc t_ In fo rmat ion /human/002148 /
WC500107728.pdf; European Medicines Agency. Pradaxa—Sum-
mary of Product Characteristics 2017 [updated January 12,
2017]. Available from: http://www.ema.europa.eu/docs/en_GB/
document_library/EPAR_-_Product_Information/human/
000829/WC500041059.pdf.
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optimal anticoagulant for patients with cancer requires
further evaluation. Some of these issues may be addressed
by clinical trials with contemporary anticoagulants already
approved for other indications rather than by development
of new anticoagulants.
Haemostasis and thrombosis are generally considered to be
manifestations of the same enzymatic and cellular processes.
Consequently, dissociation of antithrombotic and bleeding
effects might not be achievable, except perhaps for the use of
anti-FXIIa targeted therapy that should, at least from a theore-
tical point of view, be unaccompanied by a bleeding risk.100
Recent studies indicate that the ‘anatomy of a clot’ is not
homogeneous with compartmentalization of a clot into a
core and a shell.82 If the anatomy of haemostatic clot as
opposed to a thrombotic clot is different, it is possible that
novel therapeutic molecules that are able to exploit such a
difference might have a more favorable profile. The recent
report of a patient with a monoclonal IgA paraprotein
targeting thrombin who did not have an associated severe
bleeding phenotype suggests that it may be possible to target
components of coagulation with a resultant antithrombotic
effect but little if any bleeding effect.213 In this patient, the
antibody bound to exosite 1 and not the active site of
thrombin and so there may also be a kinetic basis for an
apparent dissociation of effects.
It is important to understand the animal models used to
evaluate new anticoagulants. For bleeding, the tail transection
model214 is frequently used in the preclinical evaluation of
candidate antithrombotic molecules, but it is problematic
because of the effect of vasoconstriction and that it is an
open rather than a closed bleeding model. The saphenous
vein bleeding model215 has been suggested as an alternative
that may correlate more closely with clinical bleeding pheno-
type.216 Skin bleeding time is more suited for evaluating
primary haemostasis (e.g. evaluating antiplatelet medication)
but less suited for assessing effects of anticoagulants.
To assess effects on arterial thrombosis, ultrasound-in-
duced plaque rupture in the APO-E KO mouse has been used
as a preclinical model.217 The frequently used ferric chloride-
induced thrombosis model215 recreates a predictive and re-
producible thrombus which can be subjected to inhibition by
various drugs. This can be viewed as a screening procedure,
selecting drugs only with potential inhibitory activity. How-
ever, this model does not indicate how a particular drug will
work in humans or enable ranking of drugs.
Recommendations from Theme 4
• Study the role of lower affinity PAR4 thrombin receptor
vis a vis PAR1 to establish whether PAR4 is a better target
than PAR1, because PAR4 blockade causes less bleeding.
• Develop a practically feasible PFT that reflects in vivo
platelet function and thrombus formation under physio-
logic conditions; standardize monitoring of P2Y12 inhibi-
tion; trials in high-risk patients, using clinically relevant
physiological PFTs, should be performed to assess the
relevance of PFT-based tailoring of therapy.
• Refine current risk scores in patients with AF, in particular
the decision to start anticoagulation in those with low
scores; revise CHA2DS2-VASc score and the ABC score that
includes biomarkers, also taking into account hypercoa-
gulability markers; imaging studies may provide addi-
tional information in stroke risk.
• Organize regular follow-up of patients on NOAC treat-
ment in a nurse-based manner involving anticoagulation
clinics. Regional haemostasis centres can manage com-
plex patients in a multidisciplinary manner.
• Develop separate risk scores for intracranial, GI, anduterine
bleeding in patients on oral anticoagulants to improve risk
prediction; this may also increase complexity.
• Develop, in those on NOACs, a sensitive test with short
turnaround time and 24-hour availability for emergency
situations; dose adjustment guided by laboratory assays
may be appropriate in some circumstances; the ‘therapeu-
ticwindow’ shouldbedefined, to improvedosefine-tuning.
• Try to target components of coagulation with a resultant
antithrombotic effect but little, if any, bleeding effect;
optimize preclinical testing including a better choice in
animal models, based on the model’s characteristics
related to thrombosis or bleeding.
Pleiotropy of Coagulation Proteases,
Thrombus Resolution, and Ischaemia–
Reperfusion
Clot Resolution and Ischaemia–Reperfusion Injury
Until recently, thrombectomywas considered an integral part
of the treatment strategy for acute MI. Recent meta-analyses
indicate that this is no longer tenable; only in case of heavy
thrombus burden may thrombectomy be advantageous albeit
at a potential cost of increased risk of stroke.218 For acute
ischaemic stroke, however, the MR CLEAN study has shown
that intra-arterial therapy, using for instance stent retrievers,
significantly improved patient outcome and has since gained
status of preferred treatment.219 Thrombectomy results in
biobanks containing this material and allows analysis of this
unique material to further our understanding of the throm-
botic event and the processes involved in ‘successful’ throm-
bectomy and its sequelae. The following aspects deserve
further attention:
Thrombus fragmentation and embolization. It was deemed
important to develop new and relevant ways to phenotype
the thrombus and determine its source, as current strategies
seem inadequate. Furthermore, it was considered relevant to
study the role of local fibrinolysis in embolization and
fragmentation and the composition and disease state of
the atherosclerotic vessel wall.
Stent–Thrombus interaction.We discussed which processes
might play a role in the interaction between stent and throm-
bus;220 two issues were specified: the status of the local
vasculature and of the coagulation system. With regards to
thevasculatureat thesiteof thrombectomy,TFcontent and the
depth of injury were considered possible determinants of
stent–thrombus interaction. Activation of the coagulation
system was deemed equally important, considering that
both ‘erythrocyte-rich’and ‘platelet-fibrin–rich’ thrombicould
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grow fast, within minutes, while not reflecting thrombus age.
Potentially, phenotyping based on the relative contribution of
the different leukocyte subtypes adds relevant information.
Biobanking initiatives. There are many biobanking initia-
tives but not many specifically geared toward arterial throm-
bosis. Prerequisites for successful biobanks, aside from regular
ethical considerations, were considered including (inter)na-
tional collaboration, thorough documentation of the clinical
background of thrombus and patient; procedural aspects of
thrombectomy; standardized and documented protocols for
proper handling and storage of relevant materials.
The Role of Activated Protein C in Limiting Brain
Damage in Ischaemic Stroke
Despite extensive efforts, no novel drug for ischaemic stroke
therapy has been approved in the past decade. One promising
drug candidate currently in phase II clinical studies for treat-
ment of ischaemic stroke is the activated protein C (APC)
variant 3K3A-APC.221 APC provides natural anticoagulant
function by inactivating the coagulation cofactorsVa andVIIIa.
In addition, APC conveys direct effects on cells that involve
multiple receptors including PAR1, PAR3, and the endothelial
protein C receptor (EPCR).222 Depending on the cell type and
cell stress involved, these cellular activities of APC, collectively
referred to as ‘APC’s cytoprotective activities’, can be charac-
terized as antiapoptotic and anti-inflammatory activity, ben-
eficial alterations of gene expression profiles, protection of
endothelial barrier function and regenerative activities.
Studies have shown beneficial effects of APC in rodent
stroke models.223 The use of molecularly engineered APC
variants with altered selectivity profiles to rodent stroke
models, such as the 3K3A-APC variant with minimal antic-
oagulant activity but normal cytoprotective activities, demon-
strated that the beneficial effects of APC primarily require its
cytoprotective activities but not its anticoagulant activities.
Recent insights into the molecular mechanisms for APC’s
cytoprotective activities identified noncanonical PAR1 and
PAR3 activation by APC that give rise to novel tethered ligands
capable of inducing biased cytoprotective signaling as a key
distinction from the traditional canonical thrombin-mediated
PAR1 and PAR3 signaling that generally results in prohaemo-
static and proinflammatory effects.224 Based on the available
data, the consensus model for APC’s cytoprotective activities
involves the binding of APC to the EPCR which permits APC-
mediatednoncanonical activationofPAR1atArg46andPAR3at
Arg41 resulting in the initiation of biased signaling and the
corresponding cytoprotective effects. In addition, it hasbecome
clear that additional receptors including ApoER2, MAC1, PAR2,
Tie2, factor V, and protein S are involved to provide cell-type–
specific variations to this model, but their integration into the
overall precipitation of APC’s cytoprotective activities remains
incompletely understood.
Based on the new mechanistic insights, the following
research avenues were identified:
1. To determine the effects of anticoagulant drugs on the
endogenous protein C system and in particular the ability
of the endogenous cytoprotective protein C pathway to
continue to provide beneficial effects on cells and tissues.
The (patho)physiological generation of APC by thrombin/
thrombomodulin may be affected by anticoagulant drugs
that aim to limit thrombin generation. With the increas-
ing use of direct oral anticoagulants (NOACs), questions
arise if and how these drugs affect normal APC generation
and the ability of APC to provide normal cytoprotective
effects. Protein C is also sensitive to VKAs as it contains a
GLA domain that is involved in binding of negatively
charged phospholipid vesicles required for APC’s antic-
oagulant activity, binding to EPCR required for efficient
protein C activation and APC’s cytoprotective effects on
cells. Thus, questions arise how potential effects of NOACs
compare with VKA for protein C activation and APC’s
cytoprotective effects.
2. There is an urgent need for the development of tools,
assays, and the identification of biomarkers to evaluate
the endogenous cytoprotective protein C pathway in
patient samples. Assays and tools are available for analysis
of the anticoagulant protein C pathway, but these cannot
be readily extrapolated to analysis of the cytoprotective
protein C pathway.
3. Basic research is needed to advance our understanding of
themolecular mechanisms responsible for APC’s cytopro-
tective activities. With the notion that APC induces non-
canonical activation of PAR1 and PAR3, biased signaling,
and the integration of PAR signaling based on homo- and
hetero-dimer formation, the realm of possibilities for
specialized signaling variations has grown exponentially.
New Concept of Thrombolysis and How to Improve
Clot Lysis in Ischaemic Stroke
The clinical manifestations of ischaemic stroke are hetero-
geneous and successful treatment depends on many vari-
ables involved in thrombus formation such as physical
location in the brain, time from onset, and patient-specific
variables (age, gender, comorbidities, etc.). The standard of
care for acute ischaemic stroke now involves IV alteplase
(recombinant tissue–type plasminogen activator [tPA])
within 4.5 hours, followed by antiplatelet treatment (acet-
ylsalicylic acid or clopidogrel) 24 hours after infusion of
thrombolytics, to avoid excess risk of intracerebral haemor-
rhage.225,226 The major goal of thrombolytic treatment is to
rapidly establish oxygenated blood flow to limit brain
damage. This can be achieved with thrombolytic drugs,
such as tPA, or by mechanical interventions such as endo-
vascular thrombectomy. Mechanical thrombectomy by
means of retrievable stents has been proven a very effective
treatment for acute ischaemic stroke caused by large artery
thromboembolic occlusion219,227–229 and is now accepted as
standard treatment,230,231 and incorporated in major guide-
lines.232,233 Regarding the use of thrombolytic drugs, the MR
CLEAN initiative reported that clots could only be lysed in
one-third of the patients who were treated with recombi-
nant tPA.219 This relatively low success rate has been partly
attributed to the fact that tPA only accomplishes its throm-
bolytic effect in small clots because the core of the thrombus
can be reached.234 Infusion during a longer period of time
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might improve the impact of tPA; however, it may increase
the risk of massive brain damage caused by bleeding. Mean-
while, proper reperfusion of the brain after endovascular
thrombectomy that is usually performed on patients with
large thrombi is often not achieved, for unknown reasons. It
has been suggested that the formation/release of micro-
thrombi that may diminish downstream microvascular per-
fusionmay playa role.235,236Nonetheless, reperfusion can be
visualized and analysed only in the larger vessels. These
uncertainties and side effects of current treatments for
ischaemic stroke highlight the importance of improving
drug treatment. The ideal treatment should comprise drugs
that have immediate effects to minimize brain damage, to
safely enhance fibrinolysis, and simultaneously do not cause
bleeding. This kind of treatment could be combined with
thrombectomy resulting in fast mechanical removal of most
of the thrombus and fibrinolytic removal of microthrombi.
One novel research avenue is directed at the interaction
between vWF and glycoprotein 1b, and another approach is
to infuse ADAMTS13, and both approaches appear to reduce
clot stability in models of ischaemic stroke.237,238
Another concept of safe thrombolysis combines profibri-
nolytic approaches such as anti-PAI-1, anti-thrombin acti-
vatable fibrinolysis inhibitor (anti-TAFI), and anti-α2-
antiplasmin.239 One promising strategy, for which the proof
of concept has been demonstrated inmousemodels, is based
on a bispecific diabody against TAFI and PAI-1.240 It simulta-
neously blocks the two antifibrinolytic proteins resulting in a
significantly enhanced activity of endogenous t-PA. Com-
pared with a monoclonal antibody (150 kDa), it is much
smaller (50 kDa) and thus might be able to reach the core of
the thrombus more easily. Additionally, it has a half-life of
approximately 120minutes instead of 2 to 3weeks compared
withmonoclonal antibodies. Therefore, the diabodymight be
beneficial as a safe fibrinolytic with a reduced bleeding risk.
Additionally, the possibilities of combining other fibrinoly-
tics, such as anti-α2-antiplasmin, with PAI-1 or TAFI still
needs to be investigated, as well as combining such profi-
brinolytics with thrombectomy. When designing a factorial
‘cocktail’ study, the challenge is to determine the right doses
(beneficial effect with minimal harmful side effects) of the
right combination treatments.
Recommendations from Theme 5
• Organize structured, focused biobanking initiatives to
support relevant ways of thrombus phenotyping; develop
studies to identify vessel wall-stent coagulation/fibrino-
lysis interactions.
• Determine the effects of anticoagulant drugs on the en-
dogenous protein C system including its cytoprotective
effects on cells and tissues; new tools needed to evaluate
the endogenous cytoprotective protein C pathway in pa-
tient samples; basic research to advance our understanding
of the mechanisms of APC’s cytoprotective activities.
• Improve drug treatment as well as management of pa-
tients suffering from ischaemic stroke; the possibilities of
combining fibrinolytics, such as anti-α2-antiplasmin,
with PAI-1 or TAFI needs to be investigated, as well as
combining such profibrinolytics with thrombectomy.
What is known about this topic?
• Atherothrombosis occurs secondary to atherosclero-
sis, a chronic inflammatory vascular disease.
• Detailed information on individual risk profiles con-
tributing to atherothrombosis is lacking.
• Recent insights in the diversity and functionality of
monocytes (macrophages), leukocytes, and platelets in
driving atherosclerosis and subsequent thrombosis
have become available.
• This knowledge is poorly implemented in research on
atherothrombosis.
• The contact system, factors XI and XIII, and fibrinogen/
fibrin are key players in determining net coagulation
activity.
• Recent insights suggest important interactions with
platelets, as well as inflammatory mechanisms that
link these systems.
• New avenues of antithrombotic management are
emerging, but these require refinement or tailoring.
• Improved knowledge of PAR-1 and PAR-4 signalling on
pathwayscreatesopportunities forbetter tailoredtherapy.
• Tailoring antiplatelet therapy based on platelet func-
tion assays is currently not yet feasible.
• Anticoagulation in patients with atrial fibrillation and
relatively low-risk scores is still unsettled.
• Bleeding risk scoresmay vary for different organ systems.
• Long-term anticoagulant management, specifically
with direct oral anticoagulants (DOACs), requires bet-
ter organization.
• Laboratory testing of DOAC is required under specific
conditions.
• Studies on thrombus properties are limited because of
poor quality and number of biobanking facilities.
• Activated protein C mutants are increasingly interest-
ing for their cytoprotective properties (e.g. in the
management of patients with ischaemic stroke).
• Management of patients with ischaemic stroke merits
further refinement based on promising outcomes of
studies aimed at timely clot removal.
• New developments in the field of improved clot lysis
are being explored, but the clinical impact has not been
addressed yet.
What does this paper add?
• Specific risk factors like ectopic fat need to be
considered.
• Proteomic and metabolomics data should be added to
genetic information.
• Better definitions of plaque stability contribution to
atherothrombosis are needed.
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• Mechanisms of leukocyte and macrophage plasticity,
migration and transformation in murine atherosclero-
sis need to be considered.
• Disease mechanism-based biomarkers need to be
identified.
• Develop experimental systems that incorporate whole
blood flow to understand how RBCs influence throm-
bus formation and stability.
• Knowledge on platelet heterogeneity and priming
conditions needs to be translated toward the in vivo
situation.
• The role of factor XI in thrombosis including the lower
margins of this factor related to safe and effective
antithrombotic therapy needs to be established.
• Factor XI is a key regulator in linking platelets, thrombin
generation and inflammatory mechanisms in a renin–
angiotensin-dependent manner; the impact on throm-
bin-dependent PAR signaling needs further study.
• The fundamental mechanisms in FXIII biology and
biochemistry and its impact on thrombus biophysical
characteristics need to be explored.
• The interactions of red cells and fibrin formation and
its consequences for thrombus formation and lysis
need to be addressed.
• Platelet–fibrin interactions are pivotal determinants of
clot formation and stability with potential therapeutic
consequences.
• The role of PAR-4 vis a vis PAR-1 as target for antith-
rombotic therapy merits study.
• Ongoing trials on platelet function test–based antipla-
telet therapy adjustment may support development of
practically feasible tests
• Risk scores for patients with AF need refinement,
taking new biomarkers including for coagulation into
account.
• Risk scores that consider organ system differences in
bleeding may have added value.
• NOAC treatment requires better organization, includ-
ing education and emergency access; laboratory test-
ing still needs rapidly available sensitive tests with
short turnaround time.
• Biobanks specifically for thrombus storage and analy-
sis are needed.
• Further studies on novel modified activated protein C–
based agents are required including its cytoprotective
properties.
• Newavenues for optimizing treatment of patientswith
ischaemic stroke are needed, also including novel
agents that modify fibrinolytic activity (aimed at
PAI-1 and TAFI) currently studies in subjects with
pulmonary embolism.
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